Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Zoetis (GB:0M3Q)
LSE:0M3Q
Zoetis (0M3Q) Share Price & Analysis
0 Followers
0M3Q Stock Chart & Stats
Day’s Range$159.08 - $161.91
52-Week Range― - ―
Previous Close$161.14
Volume191.21K
Average Volume (3M)N/A
Market Cap
$72.45B
Enterprise Value$79.20B
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$6.75B
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 02, 2024EPS Estimate
$1.34Last Dividend Ex-Date
Apr 18, 2024Dividend Yield1.01%
Share Statistics
EPS (TTM)N/A
Shares Outstanding457,867,115
10 Day Avg. Volume9,331
30 Day Avg. Volume3,711
Standard Deviation0.05
R-Squared0.15
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)80.59
Price to Sales (P/S)8.40
Price to Cash Flow (P/CF)20.20
P/FCF Ratio24.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue9.27
Enterprise Value/Gross Profit13.24
Enterprise Value/Ebitda21.60
Forecast
1Y Price Target
$208.29Price Target Upside30.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Zoetis News
Bulls Say, Bears Say
Bulls Say
Financial OutlookOperational revenue growth is expected to be robust, reflecting continued momentum across key products.
Market PositionZoetis is considered a market leader in an industry with durable secular growth drivers.
Product ConfidenceAnalyst remains confident in the efficacy and long-term outlook of Librela despite current concerns, indicating a strong belief in the product's future performance.
Bears Say
Earnings Performance4Q earnings Adjusted EPS comes in below estimates.
Financial GuidanceFY24 guide falls short of consensus, with initial Adj EPS guide of $5.79 at midpoint.
Regulatory ChallengesEC announces antitrust investigation on pain mAb development.
---
Options Prices
Currently, No data available
---
Ownership Overview
9.30% Insiders
27.70% Mutual Funds
22.67% Other Institutional Investors
40.33% Public Companies and
Individual Investors
0M3Q FAQ
What was Zoetis’s price range in the past 12 months?
Currently, no data Available
What is Zoetis’s market cap?
Currently, no data Available
When is Zoetis’s upcoming earnings report date?
Zoetis’s upcoming earnings report date is May 02, 2024 which is yesterday.
How were Zoetis’s earnings last quarter?
Zoetis released its earnings results on Feb 13, 2024. The company reported $1.24 earnings per share for the quarter, missing the consensus estimate of $1.316 by -$0.076.
Is Zoetis overvalued?
According to Wall Street analysts Zoetis’s price is currently Undervalued.
Does Zoetis pay dividends?
Zoetis pays a Quarterly dividend of $0.43 which represents an annual dividend yield of 1.01%. See more information on Zoetis dividends here
What is Zoetis’s EPS estimate?
Zoetis’s EPS estimate is $1.34.
How many shares outstanding does Zoetis have?
Currently, no data Available
What happened to Zoetis’s price movement after its last earnings report?
Zoetis reported an EPS of $1.24 in its last earnings report, missing expectations of $1.316. Following the earnings report the stock price went down -6.882%.
Which hedge fund is a major shareholder of Zoetis?
Among the largest hedge funds holding Zoetis’s share is Intermede Investment Partners Ltd. It holds Zoetis’s shares valued at 194M.
---
Zoetis Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$208.29 (30.14% Upside)
$208.29 (30.14% Upside)
Blogger Sentiment
Bullish
GB:0M3Q Sentiment 93%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $2.7M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-8.26%
12-Months-Change
Fundamentals
Return on Equity
49.86%
Trailing 12-Months
Asset Growth
-4.28%
Trailing 12-Months
Company Description
Zoetis
Founded in 1952, New Jersey-based Zoetis, Inc. is the world's largest manufacturer of medicine and vaccinations for pets and livestock in the United States and internationally. Its products are complemented by diagnostic products, genetic tests, bio devices and services.
---
0M3Q Company Deck
---
0M3Q Earnings Call
Q4 2024
0:00 / 0:00
---
0M3Q Revenue Breakdown
22.79% Parasiticides
20.73% Vaccines
16.70% Dermatology
14.98% Other pharmaceuticals
24.80% Other
---
0M3Q Stock 12 Months Forecast
Average Price Target
$208.29
▲(30.14% Upside)
Technical Analysis
Best Analysts Covering 0M3Q
1 Year
1 Year Success Rate
21/31 ratings generated profit
1 Year Average Return
+11.27%
reiterated a buy rating 3 days ago
Copying Jonathan Block's trades and holding each position for 1 Year would result in 67.74% of your transactions generating a profit, with an average return of +11.27% per trade.
---